Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed the day trading at $22.78 up 15.52% from the previous closing price of $19.72. In other words, the price has increased by $15.52 from its previous closing price. On the day, 10.98 million shares were traded. RARE stock price reached its highest trading level at $22.87 during the session, while it also had its lowest trading level at $19.8.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 94.23 whereas as Long-Term Debt/Eq ratio is at 85.75.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 29 ’25 when Huizenga Theodore Alan sold 85 shares for $34.38 per share. The transaction valued at 2,922 led to the insider holds 50,450 shares of the business.
Horn Howard sold 3,081 shares of RARE for $112,087 on Dec 10 ’25. The Chief Financial Officer now owns 95,146 shares after completing the transaction at $36.38 per share. On Dec 10 ’25, another insider, HOWARD HORN, who serves as the Officer of the company, bought 3,081 shares for $36.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2197758976 and an Enterprise Value of 2638682368. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.49 while its Price-to-Book (P/B) ratio in mrq is 239.44. Its current Enterprise Value per Revenue stands at 4.184 whereas that against EBITDA is -5.187.
Stock Price History:
The Beta on a monthly basis for RARE is 0.13, which has changed by -0.52077764 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $46.50, while it has fallen to a 52-week low of $18.41. The 50-Day Moving Average of the stock is -31.87%, while the 200-Day Moving Average is calculated to be -31.61%.
Shares Statistics:
Over the past 3-months, RARE traded about 1.73M shares per day on average, while over the past 10 days, RARE traded about 3520140 shares per day. A total of 96.27M shares are outstanding, with a floating share count of 89.77M. Insiders hold about 6.95% of the company’s shares, while institutions hold 99.09% stake in the company. Shares short for RARE as of 1765756800 were 8600577 with a Short Ratio of 4.96, compared to 1763078400 on 7828953. Therefore, it implies a Short% of Shares Outstanding of 8600577 and a Short% of Float of 9.229999999999999.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is -$1.47, with high estimates of -$0.91 and low estimates of -$1.77.
Analysts are recommending an EPS of between -$5.37 and -$6.41 for the fiscal current year, implying an average EPS of -$5.78. EPS for the following year is -$4.42, with 12.0 analysts recommending between -$2.68 and -$6.45.
Revenue Estimates
16 analysts predict $187.8M in revenue for. The current quarter. It ranges from a high estimate of $197M to a low estimate of $175.1M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 16 analysts are estimating revenue of $172.08M. There is a high estimate of $197.47M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $667.91M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $654.95M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $785.65M in the next fiscal year. The high estimate is $886.7M and the low estimate is $668.72M.
